Forward Progress in Molecular Markers in Prostate Cancer

Matthew R. Cooperberg, MD, MPH, explores a range of biomarkers used for diagnosis, risk stratification, and guiding treatment for prostate he cancer. He first details pre-biopsy diagnosis or prostate cancer, including PSA, 4K, phi, MyProstateScore, ExoDX, SelectMDx, and mpMRI. Dr. Cooperberg discusses how post-diagnosis biomarkers must be shown to improve on an existing, validated, multivariable model reflecting all available clinical information rather than on a single variable or nonlinear risk grouping, and reviews post-diagnosis options for risk stratification and treatment.

For more from GRU, visit our Next Generation Genomics & Biomarkers Learning Center: https://grandroundsinurology.com/next...